ADAMTS13 and thrombotic thrombocytopenic purpura: However, in cases where ADAMTS13 deficiency/inhibition occurs in the setting of a drug, the 2023 American Society for Apheresis (ASFA) guidelines indicate that a diagnosis of drug-induced or secondary TTP is more appropriate than DI-TMA [5].